Gilead Sciences | GILD - Interest Income


Gilead Sciences reported $95M in Interest Income for its fiscal quarter ending in March of 2026.





Interest Income Change Date
AbbVie USD 72M 13M Mar/2026
Agios Pharmaceuticals USD 10.8M 1.62M Mar/2026
ALKERMES USD 8.54M 3.59M Mar/2026
Alnylam Pharmaceuticals USD 26.6M 32K Mar/2026
Biogen USD 37.9M 700K Mar/2026
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Eli Lilly USD 65M 25M Sep/2025
Gilead Sciences USD 95M 0 Mar/2026
GlaxoSmithKline GBP 22M 96M Mar/2026
Glaxosmithkline GBP 22M 4M Mar/2026
Incyte USD 38.12M 4.43M Jun/2026
J&J USD 2.27 0.13 Jun/2026
Merck USD 35M 34M Mar/2026
Moderna USD 72M 2M Mar/2026
Pfizer USD -0.04 115M Jun/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 183.3M 200K Jun/2026
Sanofi EUR 77M 17M Jun/2026
Sarepta Therapeutics USD 7M 1.74M Mar/2026
United Therapeutics USD 31.5M 10.3M Jun/2026
Vertex Pharmaceuticals USD 120.6M 5.8M Jun/2026